Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Sally Susman says there's no average day in her field and explains why she doesn't see comms as a 'soft skill.' ...

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

As different stocks rise and fall, so do dividend yields, creating a shifting landscape of opportunities for income-oriented ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

The Market Access for CNS Therapeutics Summit is the only dedicated forum focused on tackling the unique commercial and ...

Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...

Chinese biotech shares are surging this year on growing optimism over innovative cancer treatments being licensed to western ...

Hemostats market was valued at US$ 2,884.13 million in 2024 and is projected to hit the market valuation of US$ 4,839.68 million by 2033 at a CAGR of 5.92% during the forecast period 2025–2033.

Pfizer faces adjusted financial forecasts as analysts lower earnings expectations for FY2025, signaling cautious optimism.

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

The country’s biggest pharmaceuticals group pointed to “specific non-allied countries” and urged the White House to ...